Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate

A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands)

Source: Annual Congress 2003 - Similarities and differences between β-2 agonists
Session: Similarities and differences between β-2 agonists
Session type: Thematic Poster Session
Number: 1855
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. J. M. Schreurs, H. L. M. van Helmond, J. H. E. Schijen, L. P. M. Greefhorst, P. G. H. Mulder (Hertogenbosch, Roosendaal, Tilburg, Hengelo, Rotterdam, The Netherlands). Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate. Eur Respir J 2003; 22: Suppl. 45, 1855

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol
Source: Eur Respir J 2004; 24: Suppl. 48, 512s
Year: 2004

Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice
Source: Eur Respir J 2001; 18: Suppl. 33, 348s
Year: 2001

Is overall asthma control being achieved? A hypothesis-generating study
Source: Eur Respir J 2001; 17: 589-595
Year: 2001



Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008

A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 458s
Year: 2007

Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations)
Source: Annual Congress 2007 - Primary care respiratory problems
Year: 2007


Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001

Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study
Source: Eur Respir J 2007; 30: Suppl. 51, 34s
Year: 2007

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017


Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial)
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004

Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Survival in COPD patients after regular use of fluticasone propionate and salmeterol
Source: Eur Respir J 2003; 21: 559-560
Year: 2003


The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis
Source: Eur Respir J 2007; 30: Suppl. 51, 352s
Year: 2007